- Home
- NXTC vs QNTM Comparison
NXTC vs QNTM Comparison
Compare NXTC & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- QNTM
- Stock Information
- Founded
- NXTC 2015
- QNTM 1998
- Country
- NXTC United States
- QNTM Canada
- Employees
- NXTC N/A
- QNTM N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- QNTM
- Sector
- NXTC Health Care
- QNTM
- Exchange
- NXTC Nasdaq
- QNTM NYSE
- Market Cap
- NXTC 13.9M
- QNTM 35.6M
- IPO Year
- NXTC 2019
- QNTM N/A
- Fundamental
- Price
- NXTC $0.49
- QNTM $13.46
- Analyst Decision
- NXTC Strong Buy
- QNTM
- Analyst Count
- NXTC 2
- QNTM 0
- Target Price
- NXTC $3.50
- QNTM N/A
- AVG Volume (30 Days)
- NXTC 141.9K
- QNTM 210.7K
- Earning Date
- NXTC 05-01-2025
- QNTM 05-14-2025
- Dividend Yield
- NXTC N/A
- QNTM N/A
- EPS Growth
- NXTC N/A
- QNTM N/A
- EPS
- NXTC N/A
- QNTM N/A
- Revenue
- NXTC N/A
- QNTM N/A
- Revenue This Year
- NXTC N/A
- QNTM N/A
- Revenue Next Year
- NXTC N/A
- QNTM N/A
- P/E Ratio
- NXTC N/A
- QNTM N/A
- Revenue Growth
- NXTC N/A
- QNTM N/A
- 52 Week Low
- NXTC $0.22
- QNTM $2.70
- 52 Week High
- NXTC $1.82
- QNTM $23.81
- Technical
- Relative Strength Index (RSI)
- NXTC 55.20
- QNTM 73.02
- Support Level
- NXTC $0.45
- QNTM $10.75
- Resistance Level
- NXTC $0.52
- QNTM $13.44
- Average True Range (ATR)
- NXTC 0.05
- QNTM 1.39
- MACD
- NXTC 0.01
- QNTM 0.22
- Stochastic Oscillator
- NXTC 66.47
- QNTM 83.46
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.